BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12141397)

  • 1. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study.
    Bada A; Casacó Parada A; Arteaga M; Martínez J; León A; Santana E; Hernández O; Orphee R; González A; Mesa C; González C; Montero E; Fernández LE
    Hum Exp Toxicol; 2002 May; 21(5):263-7. PubMed ID: 12141397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
    Mazorra Z; Mesa C; Fernández A; Fernández LE
    Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
    Ravindranath MH; Kelley MC; Jones RC; Amiri AA; Bauer PM; Morton DL
    Int J Cancer; 1998 Jan; 75(1):117-24. PubMed ID: 9426699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.
    Carr A; Rodríguez E; Arango Mdel C; Camacho R; Osorio M; Gabri M; Carrillo G; Valdés Z; Bebelagua Y; Pérez R; Fernández LE
    J Clin Oncol; 2003 Mar; 21(6):1015-21. PubMed ID: 12637465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity.
    Guthmann MD; Bitton RJ; Carnero AJ; Gabri MR; Cinat G; Koliren L; Lewi D; Fernandez LE; Alonso DF; Gómez DE; Fainboim L
    J Immunother; 2004; 27(6):442-51. PubMed ID: 15534488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.
    Nores GA; Dohi T; Taniguchi M; Hakomori S
    J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).
    Estevez F; Carr A; Solorzano L; Valiente O; Mesa C; Barroso O; Sierra GV; Fernandez LE
    Vaccine; 1999 Aug; 18(1-2):190-7. PubMed ID: 10501249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
    Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
    Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
    Ravindranath MH; Brazeau SM; Morton DL
    Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study.
    Barro AM; Rivero AI; Goñi AL; Navarro BO; Angarica MM; Ramírez BS; Bedoya DM; Triana CG; Rodríguez AM; Parada ÁC
    Vaccine; 2012 Dec; 31(1):89-95. PubMed ID: 23142132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
    Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
    Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.
    Guthmann MD; Castro MA; Cinat G; Venier C; Koliren L; Bitton RJ; Vázquez AM; Fainboim L
    J Immunother; 2006; 29(2):215-23. PubMed ID: 16531822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
    Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
    Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
    Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
    Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
    Gabri MR; Ripoll GV; Alonso DF; Gómez DE
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
    Dohi T; Nores G; Hakomori S
    Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
    Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
    Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.
    Carr A; Mullet A; Mazorra Z; Vázquez AM; Alfonso M; Mesa C; Rengifo E; Pérez R; Fernández LE
    Hybridoma; 2000 Jun; 19(3):241-7. PubMed ID: 10952412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside.
    Alfonso M; Lanne B; Ifversen P; Vázquez AM; Pérez R; Portoukalian J; Zeuthen J
    Hum Antibodies Hybridomas; 1995; 6(3):102-12. PubMed ID: 8597625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.